Lifecore Biomedical, Inc. (LFCR)
USD 6.49
(2.45%)
USD 6.49
(2.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 812 Thousand USD | 198.96% |
| 2023 | -35.97 Million USD | -152.33% |
| 2022 | 1.96 Million USD | 63.38% |
| 2021 | 13 Million USD | 203.28% |
| 2020 | -7.16 Million USD | -274.39% |
| 2019 | 23.47 Million USD | -56.76% |
| 2018 | 24.98 Million USD | 9.94% |
| 2017 | 26.67 Million USD | -1.92% |
| 2016 | -7.79 Million USD | -29.24% |
| 2015 | 30.39 Million USD | -28.13% |
| 2014 | 38.68 Million USD | -8.14% |
| 2013 | 41.56 Million USD | 54.11% |
| 2012 | 26.99 Million USD | 62.43% |
| 2011 | 14.57 Million USD | 5.59% |
| 2010 | 12.24 Million USD | -6.05% |
| 2009 | 17.04 Million USD | -27.37% |
| 2008 | 18.38 Million USD | 67.73% |
| 2007 | 33.62 Million USD | -10.55% |
| 2006 | 12.22 Million USD | 29.11% |
| 2005 | 9.48 Million USD | 22.73% |
| 2004 | 7.76 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 4.75 Million USD | 60.99% |
| 2001 | 2.78 Million USD | -55.58% |
| 2000 | 4.28 Million USD | 800.89% |
| 1999 | -2.29 Million USD | 52.63% |
| 1998 | -1.2 Million USD | 80.21% |
| 1997 | -7.9 Million USD | -45.45% |
| 1996 | -3.8 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 880 Thousand USD | 113.72% |
| 2024 Q1 | -6.45 Million USD | 76.17% |
| 2024 Q3 | 4.31 Million USD | 139.66% |
| 2024 FY | - USD | 107.3% |
| 2024 Q4 | 4.28 Million USD | 119.96% |
| 2023 Q1 | -2.5 Million USD | 18.44% |
| 2023 Q2 | -3.87 Million USD | -54.51% |
| 2023 Q4 | -2.59 Million USD | 30.66% |
| 2023 FY | - USD | -152.33% |
| 2023 Q3 | -3.74 Million USD | 3.3% |
| 2022 Q3 | 6.11 Million USD | 150.49% |
| 2022 Q1 | 3.94 Million USD | -64.81% |
| 2022 Q2 | 2.44 Million USD | -38.08% |
| 2022 Q4 | -3.07 Million USD | -150.27% |
| 2022 FY | - USD | 63.38% |
| 2021 Q4 | 11.2 Million USD | 60.71% |
| 2021 FY | - USD | 203.28% |
| 2021 Q3 | 6.97 Million USD | 171.03% |
| 2021 Q1 | -4.07 Million USD | -224.86% |
| 2021 Q2 | -9.81 Million USD | -140.81% |
| 2020 Q1 | -4.35 Million USD | -273.37% |
| 2020 FY | - USD | -274.39% |
| 2020 Q2 | -1.49 Million USD | 65.79% |
| 2020 Q3 | -1.37 Million USD | 8.05% |
| 2020 Q4 | -1.25 Million USD | 8.39% |
| 2019 Q3 | 2.66 Million USD | 219.78% |
| 2019 FY | - USD | -56.76% |
| 2019 Q4 | 2.51 Million USD | -5.81% |
| 2019 Q1 | 599 Thousand USD | -93.21% |
| 2019 Q2 | 834 Thousand USD | 39.23% |
| 2018 Q4 | 8.82 Million USD | 167.83% |
| 2018 Q3 | 3.29 Million USD | 318.15% |
| 2018 Q2 | 788 Thousand USD | -77.18% |
| 2018 Q1 | 3.45 Million USD | 30.65% |
| 2018 FY | - USD | 9.94% |
| 2017 Q1 | 8.02 Million USD | 9.92% |
| 2017 FY | - USD | -1.92% |
| 2017 Q4 | 2.64 Million USD | -73.12% |
| 2017 Q3 | 9.83 Million USD | 383.48% |
| 2017 Q2 | 2.03 Million USD | -74.65% |
| 2016 FY | - USD | -29.24% |
| 2016 Q3 | 394 Thousand USD | -86.97% |
| 2016 Q4 | 7.3 Million USD | 1752.79% |
| 2016 Q1 | 4.76 Million USD | -28.3% |
| 2016 Q2 | 3.02 Million USD | -36.6% |
| 2015 Q3 | 6.22 Million USD | 20.08% |
| 2015 Q4 | 6.65 Million USD | 6.84% |
| 2015 FY | - USD | -28.13% |
| 2015 Q2 | 5.18 Million USD | -2.94% |
| 2015 Q1 | 5.34 Million USD | -26.68% |
| 2014 Q4 | 7.28 Million USD | -28.67% |
| 2014 Q2 | 5.52 Million USD | -25.74% |
| 2014 Q1 | 7.43 Million USD | 23.93% |
| 2014 FY | - USD | -8.14% |
| 2014 Q3 | 10.21 Million USD | 84.9% |
| 2013 Q3 | 7.75 Million USD | -5.19% |
| 2013 Q1 | 4.38 Million USD | -21.87% |
| 2013 Q4 | 6 Million USD | -22.6% |
| 2013 Q2 | 8.17 Million USD | 86.33% |
| 2013 FY | - USD | 54.11% |
| 2012 Q2 | 4.29 Million USD | 45.47% |
| 2012 Q4 | 5.61 Million USD | 37.04% |
| 2012 FY | - USD | 62.43% |
| 2012 Q1 | 2.94 Million USD | 270.36% |
| 2012 Q3 | 4.09 Million USD | -4.48% |
| 2011 FY | - USD | 5.59% |
| 2011 Q2 | 3.64 Million USD | -9.78% |
| 2011 Q3 | 3.91 Million USD | 7.33% |
| 2011 Q4 | -1.73 Million USD | -144.25% |
| 2011 Q1 | 4.04 Million USD | 479.63% |
| 2010 FY | - USD | -6.05% |
| 2010 Q3 | 2.88 Million USD | 12.7% |
| 2010 Q1 | 3.64 Million USD | -11.48% |
| 2010 Q2 | 2.55 Million USD | -29.87% |
| 2010 Q4 | 697 Thousand USD | -75.83% |
| 2009 Q2 | 3.06 Million USD | -42.86% |
| 2009 FY | - USD | -27.37% |
| 2009 Q4 | 4.12 Million USD | 19.97% |
| 2009 Q1 | 5.35 Million USD | 50.89% |
| 2009 Q3 | 3.43 Million USD | 12.29% |
| 2008 Q2 | 4.58 Million USD | 6.04% |
| 2008 FY | - USD | 67.73% |
| 2008 Q4 | 3.54 Million USD | -40.48% |
| 2008 Q3 | 5.96 Million USD | 30.11% |
| 2008 Q1 | 4.32 Million USD | -10.11% |
| 2007 FY | - USD | -10.55% |
| 2007 Q4 | 4.8 Million USD | 10.17% |
| 2007 Q3 | 4.36 Million USD | 325.76% |
| 2007 Q2 | 1.02 Million USD | 34.87% |
| 2007 Q1 | 760 Thousand USD | -90.08% |
| 2006 Q1 | 417 Thousand USD | -91.76% |
| 2006 FY | - USD | 29.11% |
| 2006 Q2 | -118 Thousand USD | -128.3% |
| 2006 Q3 | 4.28 Million USD | 3732.2% |
| 2006 Q4 | 7.66 Million USD | 78.84% |
| 2005 Q3 | 3.55 Million USD | 1008.41% |
| 2005 FY | - USD | 22.73% |
| 2005 Q4 | 5.06 Million USD | 42.24% |
| 2005 Q2 | 321 Thousand USD | -41.53% |
| 2005 Q1 | 549 Thousand USD | -89.58% |
| 2004 Q1 | 644 Thousand USD | -88.99% |
| 2004 Q3 | 1.96 Million USD | 1435.37% |
| 2004 Q4 | 5.27 Million USD | 168.52% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | -147 Thousand USD | -122.83% |
| 2003 Q2 | 16 Thousand USD | 172.86% |
| 2003 Q3 | -992 Thousand USD | -1163.73% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | 5.78 Million USD | 639.08% |
| 2003 Q1 | 305 Thousand USD | -102.08% |
| 2002 Q4 | 6.62 Million USD | 407.62% |
| 2002 Q1 | -8000.00 USD | -82.95% |
| 2002 Q2 | -1.38 Million USD | -251.02% |
| 2002 Q3 | -2.18 Million USD | -63.83% |
| 2002 FY | - USD | 60.99% |
| 2001 Q4 | 5.46 Million USD | 367.34% |
| 2001 Q3 | -2.16 Million USD | -227.64% |
| 2001 Q2 | 1.13 Million USD | -2.87% |
| 2001 Q1 | 1.49 Million USD | -65.55% |
| 2001 FY | - USD | -55.58% |
| 2000 FY | - USD | 800.89% |
| 2000 Q2 | -2.2 Million USD | -57.14% |
| 2000 Q4 | 4.74 Million USD | 425.07% |
| 2000 Q3 | -1.3 Million USD | 36.36% |
| 2000 Q1 | -1.4 Million USD | -136.84% |
| 1999 Q1 | -1 Million USD | -141.38% |
| 1999 Q2 | -2.1 Million USD | -83.33% |
| 1999 Q3 | -1.2 Million USD | 40.91% |
| 1999 Q4 | 3.92 Million USD | 392.31% |
| 1999 FY | - USD | 52.63% |
| 1998 Q2 | -600 Thousand USD | 21.43% |
| 1998 Q3 | -1.2 Million USD | -36.36% |
| 1998 Q4 | 3.1 Million USD | 293.33% |
| 1998 FY | - USD | 80.21% |
| 1998 Q1 | -1 Million USD | 72.55% |
| 1997 FY | - USD | -45.45% |
| 1997 Q2 | -1.9 Million USD | -33.33% |
| 1997 Q3 | -1.8 Million USD | 4.17% |
| 1997 Q4 | -4.2 Million USD | -121.74% |
| 1997 Q1 | -1.8 Million USD | -63.64% |
| 1996 Q3 | 400 Thousand USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | -1.1 Million USD | -375.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 99.737% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 134.538% |
| Embecta Corp. | 245.4 Million USD | 99.669% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 99.502% |
| PainReform Ltd. | -9.56 Million USD | 108.486% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 121.232% |
| SCYNEXIS, Inc. | 73.47 Million USD | 98.895% |
| Journey Medical Corporation | 1.92 Million USD | 57.73% |
| Safety Shot Inc | -12.18 Million USD | 106.664% |
| Alpha Teknova, Inc. | -25.53 Million USD | 103.179% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 99.219% |
| Alvotech | -484.86 Million USD | 100.167% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 99.257% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 31.303% |
| Cosmos Health Inc. | -17.06 Million USD | 104.759% |
| Dynavax Technologies Corporation | 9.66 Million USD | 91.599% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 100.541% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 100.511% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 121.232% |
| Theratechnologies Inc. | -10.31 Million USD | 107.874% |
| Harrow Health, Inc. | 9.72 Million USD | 91.649% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 117.945% |
| Biofrontera Inc. | -18.45 Million USD | 104.4% |
| DURECT Corporation | -24.68 Million USD | 103.29% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 99.174% |
| Cronos Group Inc. | -72.14 Million USD | 101.125% |
| OptiNose, Inc. | -15.55 Million USD | 105.221% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 100.088% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 102.25% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 96.909% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 97.746% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 120.702% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 214.229% |
| Radius Health, Inc. | 38.31 Million USD | 97.88% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 125.256% |
| ProPhase Labs, Inc. | -14.82 Million USD | 105.476% |
| Phibro Animal Health Corporation | 84.6 Million USD | 99.04% |
| Procaps Group S.A. | 104.02 Million USD | 99.219% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 109.666% |
| Viatris Inc. | 3.51 Billion USD | 99.977% |
| Rockwell Medical, Inc. | -4.69 Million USD | 117.299% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 180.237% |
| SIGA Technologies, Inc. | 84.15 Million USD | 99.035% |
| Tilray Brands, Inc. | -72.84 Million USD | 101.115% |
| Shineco, Inc. | -26.55 Million USD | 103.058% |
| PetIQ, Inc. | 81.48 Million USD | 99.004% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 122.446% |
| Incannex Healthcare Limited | -18.5 Million USD | 104.388% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 99.805% |
| Alimera Sciences, Inc. | 7.27 Million USD | 88.84% |
| Silver Spike Investment Corp. | 7.34 Million USD | 88.937% |
| Assertio Holdings, Inc. | -222.44 Million USD | 100.365% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 120.348% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 119.279% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 104.832% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 104.054% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 100.545% |
| Hempacco Co., Inc. | -12.77 Million USD | 106.357% |
| Talphera, Inc. | -9.84 Million USD | 108.25% |
| Alvotech | -484.86 Million USD | 100.167% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 98.952% |
| Lantheus Holdings, Inc. | 491 Million USD | 99.835% |
| Currenc Group, Inc. | -1.9 Million USD | 142.724% |
| Kamada Ltd. | 21.53 Million USD | 96.229% |
| Indivior PLC | 66 Million USD | 98.77% |
| Evoke Pharma, Inc. | -7.29 Million USD | 111.135% |
| Flora Growth Corp. | -45.87 Million USD | 101.77% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 104.054% |
| Evolus, Inc. | -41.81 Million USD | 101.942% |
| HUTCHMED (China) Limited | 25.52 Million USD | 96.819% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 99.664% |
| Akanda Corp. | -27.73 Million USD | 102.928% |